Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023)
Supernus Pharmaceuticals (SUPN) reported Notes Payables of $402.5 million for Q1 2023, little changed quarter-over-quarter from $402.0 million in Q4 2022.
Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 2 years of Notes Payables data on file, last reported at $402.5 million in Q1 2023.
- Notes Payables for Q1 2023 came in at $402.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $402.5 million (changed N/A YoY), and the FY2022 annual result was $402.0 million, changed N/A from the prior year.
- Notes Payables held at $402.5 million in Q1 2023 per SUPN's latest filing, from $402.0 million in the prior quarter.
- Over five years, Notes Payables peaked at $402.5 million in Q1 2023 and troughed at $402.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 402.50 Mn |
| Dec 31, 2022 | 401.97 Mn |